Proteomics International Laboratories Ltd (ASX:PIQ) has been invited to feature on the American Diabetes Association (ADA) TV News Network as a key opinion leader on diabetic kidney disease diagnostics during the ADA 79th Scientific Sessions conference in San Francisco.
The company has been asked to feature the Promarker D, a blood test which can diagnose and predict whether a patient will develop diabetic kidney disease and can predict the onset of diabetic kidney disease before clinical symptoms appear.
Proteomics’ attendance at the BIO International Convention in Philadelphia and now the ADA conference showcases PromarkerD and provides the opportunity to meet with tier-1 national diagnostic groups.
“A major difference for patients”
Proteomics managing director Richard Lipscombe said: “The PromarketD test can make a major difference for patients, healthcare providers and insurance companies because it could cut dramatically the number of people who are unaware, they have progressive kidney disease.
“An early diagnosis will enable patients to do something about it immediately and so reduce the potential of costly kidney dialysis.”
PromarketD has been rated the world’s leading diagnostic test for diabetic kidney disease by the global research house Frost & Sullivan in its independent industry report titled Biomarkers Enabling Diabetes and Obesity Management.
The test has also received patent protection in several major jurisdictions including the USA, China, Europe and Japan with others pending.